To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
The Investigator's Brochure (IB) is a basic document which is required in a clinical trial of a new drug (that is, one not yet approved by regulatory authorities for sale), together with the clinical trial protocol. The IB contains both clinical and non-clinical data pertaining to the new drug. The pharmaceutical company sponsoring the study provides a copy to each principal investigator (local researcher) prior to the start of a clinical trial.
Additional recommended knowledge
According to United States FDA regulations (Title 21 CFR 312.23), an Investigator's Brochure must contain:
At the moment when a new drug enters a Phase I clinical trial, the Investigator's Brochure must contain preclinical information about the pharmacological and toxicological effects and the pharmacokinetics and biological disposition in animals. As the drug continues through Phase II and III clinical trials, information relating to safety and effectiveness (efficacy) in humans obtained from prior clinical studies must be included in the document. In addition, the IB must include possible risks and side effects to be anticipated on the basis of the sponsor's or others' prior experience with the drug under investigation or with related drugs.
As part of its guidance on Good clinical practice (GCP), the International Conference on Harmonisation (ICH) has prepared a detailed guidance for the contents of the Investigator's Brochure in the European Union, Japan, and the United States.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Investigator's_Brochure". A list of authors is available in Wikipedia.|